Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M3EA
|
|||
| Drug Name |
2-pyrazinone derivative 6
|
|||
| Synonyms |
PMID26118988-Compound-33
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H19N7O2
|
|||
| Canonical SMILES |
CC1=C(N=C(C(=O)N1C2=CC=CC(=C2)C#N)C(=O)NC3CC3)C4=CC=NN4C5=CC=C(C=C5)C#N
|
|||
| InChI |
1S/C26H19N7O2/c1-16-23(22-11-12-29-33(22)20-9-5-17(14-27)6-10-20)31-24(25(34)30-19-7-8-19)26(35)32(16)21-4-2-3-18(13-21)15-28/h2-6,9-13,19H,7-8H2,1H3,(H,30,34)
|
|||
| InChIKey |
GJIYKCWSHGJDFQ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neutrophil elastase (NE) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Neutrophil elastase (NE) | Target's Patent Info | [1] | |
| KEGG Pathway | Transcriptional misregulation in cancer | |||
| Systemic lupus erythematosus | ||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| C-MYB transcription factor network | ||||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| WikiPathways | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
| Human Complement System | ||||
| Degradation of collagen | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.